摘要
目的评价重组人血小板生成素（rhTPO）治疗肺癌患者化疗后血小板减少的临床疗效和安全性。方法51例肺癌患者在化疗后出现不同程度的血小板减少，根据其血小板下降程度分为轻度、中度、重度组，均给予rhTPO治疗，同时监测血常规、肝肾功能、凝血功能。结果51例肺癌患者血小板轻度、中度、重度抑制者分别有24、15和12例，rhTPO持续用药时间分别为（5．3±2．8）、（6．3±3．2）和（5．6±2．8）d，3组间差异无统计学意义（P=0．595）。血小板开始恢复时间和血小板减少持续时间，轻度组明显低于中度组与重度组（均P〈0．01）；rhTPO治疗后，3组患者血小板恢复最高值和血小板提高最大值差异无统计学意义（均P〉0．05）；3组外源性血小板输注情况比较，差异有统计学意义（P〈0．01），随着血小板减少程度的加重，外源性血小板输注比例增加。结论rhTPO可用于治疗肺癌患者化疗后出现的Ⅲ、Ⅳ度血小板减少，不良反应轻微。
Objective To evaluate the efficacy and safety of recombinant human thrombopoietin （rhTPO） in treatment for chemotherapy-induced thrombocytopenia in patients with lung cancer. Methods Fiftyone lung cancer patients with platelet count 〈 100 x 10^9/L after chemotherapy were enrolled into this study. They were divided into three groups： mild, moderate and severe thrombocytopenia groups according to the platelet count, rhTPO was subcutaneously administered at a dosage of 300 μg · kg^-1 · d^-1 until the platelet count ≥ 100 ×10^9/L or absolute value of platelet count ≥ 50 × 10^9/L. Laboratory tests included routine blood count, serum biochemistry, and blood coagulation test. Results The duration of the chemotherapy- induced thrombocytopenia was significantly shorter in the mild group than that in the moderate and severe groups （P 〈0. 01 ）. After administration of rhTPO, the time of declined platelet count beginning to recover was also significantly shorter in the mild group than that in the moderate and severe groups （P 〈 0.01 ）. There was a statistically significant difference in platelet transfusion needed among the three groups （ P 〈 0.01 ）. However, no significant difference was found among the three groups in the time of rhTPO treatment （P 〉 0.05） and platelet count improvement （P 〉 0. 05）. Conclusion Recombinant human thrombopaietin can be effectively and safely administered to deal with grade Ⅲ/Ⅳ chemotherapy-induced thrombocytopenia in lung cancer patients with mild adverse effects.
出处
《中华肿瘤杂志》
CAS
CSCD
北大核心
2008年第9期716-719,共4页
Chinese Journal of Oncology
关键词
血小板减少
重组人血小板生成素
肺癌
Thrombocytopenia
Recombinant human thrombopoietin
Lung neoplasms
